Synergistic Cisplatin/Doxorubicin Combination Chemotherapy for Multidrug-Resistant Cancer via Polymeric Nanogels Targeting Delivery

ACS Appl Mater Interfaces. 2017 Mar 22;9(11):9426-9436. doi: 10.1021/acsami.6b16844. Epub 2017 Mar 8.

Abstract

Combination chemotherapy has been proposed to achieve synergistic effect and minimize drug dose for cancer treatment in clinic application. In this article, the stimuli-responsive polymeric nanogels (<100 nm in size) based on poly(acrylic acid) were designed as codelivery system for doxorubicin and cisplatin to overcome drug resistance. By chelation, electrostatic interaction, and π-π stacking interactions, the nanogels could encapsulate doxorubicin and cisplatin with designed ratio and high capacity. Compared with free drugs, the nanogels could deliver more drugs into MCF-7/ADR cells. Significant accumulation in tumor tissues was observed in the biodistribution experiments. The in vitro antitumor studies demonstrated the superior cell-killing activity of the nanogel drug delivery system with a combination index of 0.84, which indicated the great synergistic effect. All the antitumor experimental data revealed that the combination therapy was effective for the multidrug-resistant MCF-7/ADR tumor with reduced side effects.

Keywords: CDDP; combination chemotherapy; doxorubicin; multidrug-resistant; nanogel; stimuli-responsive.

MeSH terms

  • Cisplatin
  • Doxorubicin
  • Drug Delivery Systems
  • Drug Resistance, Neoplasm
  • Drug Therapy, Combination
  • Humans
  • MCF-7 Cells
  • Nanoparticles*

Substances

  • Doxorubicin
  • Cisplatin